South Texas Money Management Ltd adds Edwards Lifesciences Corp (EW) to its portfolio

Edwards Lifesciences Corp (EW) : South Texas Money Management Ltd added new position in Edwards Lifesciences Corp during the most recent quarter end. The investment management firm now holds 97,390 shares of Edwards Lifesciences Corp which is valued at $11,040,130 , the company said in a statement filed on Aug 1, 2016 with the SEC.Edwards Lifesciences Corp makes up approximately 0.60% of South Texas Money Management Ltd’s portfolio.

Other Hedge Funds, Including , Rhenman Partners Asset Management Ab boosted its stake in EW in the latest quarter, The investment management firm added 15,000 additional shares and now holds a total of 70,000 shares of Edwards Lifesciences Corp which is valued at $7,935,200. Edwards Lifesciences Corp makes up approx 1.27% of Rhenman Partners Asset Management Ab’s portfolio.First Quadrant L Pca boosted its stake in EW in the latest quarter, The investment management firm added 700 additional shares and now holds a total of 63,300 shares of Edwards Lifesciences Corp which is valued at $6,754,743. Edwards Lifesciences Corp makes up approx 0.14% of First Quadrant L Pca’s portfolio.Cutler Group Lp boosted its stake in EW in the latest quarter, The investment management firm added 15,533 additional shares and now holds a total of 22,930 shares of Edwards Lifesciences Corp which is valued at $2,441,816. Edwards Lifesciences Corp makes up approx 0.17% of Cutler Group Lp’s portfolio.

Edwards Lifesciences Corp closed down -0.38 points or -0.34% at $112.98 with 7,32,535 shares getting traded on Thursday. Post opening the session at $113.65, the shares hit an intraday low of $112.59 and an intraday high of $113.99 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *